menu
    • menu

    Company profile for Tempest Therapeutics

    NEW Drugs in Dev: 3
    LGM Pharma accelerates & optimizes the new product pathway from early development through commercialization.

    Virtual Booth

    Contact Supplier

    Sharp is a leader in commercial packaging, clinical services, and sterile manufacturing.

    Virtual Booth

    Contact Supplier

    pharmacompass-1-m-2026-04-20

    Virtual Booth

    Contact Supplier

    As a CDMO, Mikart offers integrated CDMO services for Solid Dose & Non-sterile Liquid formulations.

    Virtual Booth

    Contact Supplier

    Trusted Global CDMO Partner Delivering End-to-End Pharma Manufacturing & Development Solutions.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2026-04-20

    Virtual Booth

    Contact Supplier

    EVENTS

    DIGITAL CONTENT

    DEVELOPMENTS

    REF. STANDARDS & IMPURITIES

    PharmaCompass

    Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

    Update your Virtual Booth on PharmaCompass, ask us

    About

    Tempest has a balanced and deep pipeline consisting of first-in-class and best-in-class small molecule therapeutics, which modulate distinct pathways relevant to mounting an effective anti-tumor response. Tempest has assembled an experienced team of small molecule and immuno-oncology drug developers to advance these programs to the clinic across diverse cancers representing significant unmet medical need. Tempest is backed by ...
    Tempest has a balanced and deep pipeline consisting of first-in-class and best-in-class small molecule therapeutics, which modulate distinct pathways relevant to mounting an effective anti-tumor response. Tempest has assembled an experienced team of small molecule and immuno-oncology drug developers to advance these programs to the clinic across diverse cancers representing significant unmet medical need. Tempest is backed by a syndicate of leading US and China-based venture capital firms.

    List your booth number for exhibitions, ask us

    CONTACT DETAILS

    Click the arrow to open the dropdown
    Contact SupplierContact
    Google MapGoogle Map
    Full View ScreenFull View Screen
    Tempest TherapeuticsUnited_States_of_America Flag
    Country
    Country
    U.S.A
    Address
    Address
    7000 Shoreline Court Suite 275 South San Francisco, CA 94080
    Telephone
    Telephone
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://www.tempesttx.com/
    Linkedin
    Linkedin
    https://www.linkedin.com/company/tempesttx
    youtube
    YouTube
    Twitter
    Twitter

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Events

    Webinars & Exhibitions

    Request a meetingRequest a meeting
    Full Screen ViewFull Screen View
    RDD

    RDD

    Not Confirmed

    envelop Contact Supplier

    RDD

    Post an Enquiry

    Meeting

    Digital content

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Tempest Presents Clinical Update At ISCT 2026 Annual Meeting
    Tempest Presents Clinical Update At ISCT 2026 Annual Meeting

    06 May 2026

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2026/05/06/3288654/0/en/tempest-presents-clinical-update-at-isct-2026-annual-meeting.html

    GLOBENEWSWIRE
    06 May 2026
    Share Share
    Tempest Shares Dual CAR-T Clinical Update at ISCT Meeting
    Tempest Shares Dual CAR-T Clinical Update at ISCT Meeting

    29 Apr 2026

    // FIRSTWORD PHARMA

    https://firstwordpharma.com/story/7247362

    FIRSTWORD PHARMA
    29 Apr 2026
    Share Share
    Tempest Appoints Andrew Fang, Ph.D. As Head Of Business
    Tempest Appoints Andrew Fang, Ph.D. As Head Of Business

    14 Apr 2026

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2026/04/14/3273302/0/en/Tempest-Appoints-Andrew-Fang-Ph-D-as-Head-of-Business-Development-to-Advance-Strategic-Partnerships-and-Global-Licensing-Efforts.html

    GLOBENEWSWIRE
    14 Apr 2026
    Share Share
    Tempest Reveals 2025 Financials And Business Update
    Tempest Reveals 2025 Financials And Business Update

    30 Mar 2026

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2026/03/30/3264681/0/en/Tempest-Reports-Year-End-2025-Financial-Results-and-Provides-Business-Update.html

    GLOBENEWSWIRE
    30 Mar 2026
    Share Share
    Tempest Therapeutics Announces Up To $6 Million Private Placement
    Tempest Therapeutics Announces Up To $6 Million Private Placement

    23 Mar 2026

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2026/03/23/3260325/0/en/Tempest-Therapeutics-Announces-Up-To-6-Million-Private-Placement.html

    GLOBENEWSWIRE
    23 Mar 2026
    Share Share
    Tempest Partners on TPST-2003 Ahead of US Registrational Study
    Tempest Partners on TPST-2003 Ahead of US Registrational Study

    11 Mar 2026

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2026/03/11/3253691/0/en/Tempest-Announces-Partnership-for-TPST-2003-in-Preparation-for-Planned-U-S-Registrational-Study-in-2026.html

    GLOBENEWSWIRE
    11 Mar 2026
    Share Share

    REF. STANDARDS & IMPURITIES

    Upload your portfolio for free, ask us

    ABOUT THIS PAGE

    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty
    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search